WPD Pharmaceuticals Inc. (CNSX: WBIO)
Health Care · Biotechnology · CA
CA$—
— today · — 1Y
WPD Pharmaceuticals Inc. (CNSX: WBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $233.63K and employs 16 people.
trading between 0.07 and 1.13.
Tweenvest scores WPD Pharmaceuticals Inc. across four factors: quality 20/100, value 62/100. Its strongest factor is value.
WBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $233.63K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -0.10
- 52-week high
- CA$1.13
- 52-week low
- CA$0.07
- Avg volume (3M)
- —
- Shares outstanding
- 4.64M
- Employees
- 16
- Next earnings
- —
About WPD Pharmaceuticals Inc.
WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.
- ISIN
- CA92941F2044
- Listed since
- Feb 9, 2009
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Albert Labs International Corp.CNSX: ABRT | $271.79K | CA$— | — |
| Zenith Capital Corp.OTCPK: ZHCL.F | $257.79K | $0.00 | +300.00% |
| Chimeric Therapeutics LimitedASX: CHM | $246.44K | AU$— | — |
| Nextel Medical Corp.OTCPK: MAJI | $239.24K | $0.00 | -2.93% |
| Beroni Group LimitedOTCPK: BNIG.F | $216.88K | $— | — |
| NAVCO Pharmaceuticals Inc.TSXV: NAV | $200.86K | CA$0.01 | — |
| Ocean Biomedical, Inc.OTCPK: OCEA | $185.89K | $0.00 | +60.00% |
| Endonovo Therapeutics, Inc.OTCPK: ENDV | $180.76K | $0.00 | +100.00% |
Figures last refreshed Oct 18, 2026.